Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

被引：0
|
作者：
Meng, Xiang-Yu [1 ,2 ]
Wu, Qiu-Ji [3 ]
机构：
[1] Hubei Minzu Univ, Hlth Sci Ctr, Enshi 445000, Peoples R China
[2] Hubei Minzu Univ, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Enshi 445000, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol,Hubei Key Lab Tumour Biol, Wuhan 430071, Peoples R China
来源：
EPIGENOMICS | 2023年 / 15卷 / 22期
关键词：
biomarker; molecularly matched therapy; prognosis; targeted therapy; tumor mutation burden;
D O I：
10.2217/epi-2023-0354
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：1175 / 1178
页数：4
相关论文
共 50 条
  • [1] Tumour mutational burden and survival with molecularly matched therapy
    de Bortoli, Till
    Benary, Manuela
    Horak, Peter
    Lamping, Mario
    Stintzing, Sebastian
    Tinhofer, Ingeborg
    Leyvraz, Serge
    Schaefer, Reinhold
    Klauschen, Frederick
    Keller, Ulrich
    Stenzinger, Albrecht
    Froehling, Stefan
    Kurzrock, Razelle
    Keilholz, Ulrich
    Rieke, Damian T.
    Jelas, Ivan
    EUROPEAN JOURNAL OF CANCER, 2023, 190
  • [2] Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts
    Jelas, I
    de Bortoli, T.
    Benary, M.
    Horak, P.
    Lamping, M.
    Schaefer, R.
    Klauschen, F.
    Tinhofer-Keilholz, I
    Leyvraz, S.
    Keller, U.
    Stenzinger, A.
    Froehling, S.
    Stintzing, S.
    Kurzrock, R.
    Keilholz, U.
    Rieke, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 89 - 90
  • [3] Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.
    Rieke, Damian Tobias
    De Bortoli, Till
    Benary, Manuela
    Horak, Peter
    Lamping, Mario
    Stintzing, Sebastian
    Tinhofer, Ingeborg
    Leyvraz, Serge
    Schaefer, Reinhold
    Klauschen, Frederick
    Keller, Ulrich
    Stenzinger, Albrecht
    Froehling, Stefan
    Kurzrock, Razelle
    Jelas, Ivan
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Statin Therapy for Elevated hsCRP: More Evidence Is Needed
    Molokwu, Ogochukwu C.
    AMERICAN JOURNAL OF MANAGED CARE, 2010, 16 (08): : 565 - 566
  • [5] Is Tumor Mutation Burden a predictive Marker for AJCC Stage II Melanoma?
    Sinnberg, T.
    Niessner, H.
    Amaral, T.
    Eigentler, T.
    Schroeder, C.
    Lindner, E. S.
    Hilke, F. J.
    Bonzheim, I.
    Fend, F.
    Riess, O.
    Garbe, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 19 - 19
  • [6] Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
    Wang, Peipei
    Chen, Yueyun
    Wang, Chun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Moderately hypofractionated breast radiation therapy: is more evidence needed?
    Marta, Gustavo Nader
    Poortmans, Philip
    LANCET ONCOLOGY, 2019, 20 (05): : E226 - E226
  • [8] Moderately hypofractionated breast radiation therapy: is more evidence needed? reply
    Wang, Shu-Lian
    Li, Ye-Xiong
    LANCET ONCOLOGY, 2019, 20 (05): : E227 - E227
  • [9] Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
    Zheng, Ming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [10] Tumor Mutation Burden and Efficacy of Molecular Targeted Therapy in Lung Cancer
    Arai, K.
    Sakamoto, T.
    Yamane, K.
    Hirayama, Y.
    Teruya, Y.
    Yanai, M.
    Kinoshita, N.
    Yamaguchi, K.
    Makino, H.
    Kodani, M.
    Igishi, T.
    Yamasaki, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S846 - S847
12345